{"id":"W2192572578","doi":"10.1158/1078-0432.ccr-15-1681","title":"A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"National Cancer Institute; Bayer HealthCare","keywords":"Sorafenib; Pharmacokinetics; Medicine; Tolerability; Pharmacodynamics; Dosing; Pharmacology; Internal medicine; Hepatocellular carcinoma; Adverse effect; Cancer; Oncology; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001318732,0.001535131,0.002028765,0.0003743789,0.0003421284,0.0006764138,0.0008097906,0.0006579192,0.00182979],"category_scores_gemma":[0.0008890594,0.0007025847,0.001133975,0.0004244951,0.0007450155,0.0007114331,0.0003018752,0.002407472,0.0005214419],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007661125,"about_ca_system_score_gemma":0.001367136,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004599716,"about_ca_topic_score_gemma":0.001079156,"domain_scores_codex":[0.9993483,0.000299126,0.00003938477,0.000124707,0.00009631382,0.00009215228],"domain_scores_gemma":[0.9991999,0.0001304714,0.0002046136,0.0001067846,0.00004940193,0.0003088177],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5130092,0.1325841,0.01875129,0.0008086016,0.001754787,0.0005870821,0.0004412511,0.005850504,0.1561683,0.0002552259,0.002383158,0.1674065],"study_design_scores_gemma":[0.2305438,0.7365344,0.01812967,0.00002007739,0.0004019015,0.000654995,0.00004177371,0.00213444,0.009396119,0.00009428811,0.002007213,0.00004135391],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973342,0.0006619161,0.000441645,0.0001181355,0.00003561409,0.0006496374,0.0002230279,0.00003479532,0.0005008322],"genre_scores_gemma":[0.9950762,0.0006422357,0.001695484,0.0002106885,0.0001026254,0.0007208661,0.0008575449,0.00001677811,0.0006775124],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002028765,"threshold_uncertainty_score":0.00697422,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1180769002499015,"score_gpt":0.4794947159108082,"score_spread":0.3614178156609067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}